Healthcare Private Equity Market 2025: Resurgence and Record Growth

Healthcare PE in 2025: A Record-Breaking Year

The healthcare private equity market delivered an extraordinary performance in 2025, shattering previous records and signaling a powerful resurgence after several years of more measured activity. Global healthcare PE deal value exceeded an estimated $191 billion, surpassing the previous high set during the exuberant market of 2021. This milestone was not driven by a single outlier transaction but rather by a broad-based recovery across geographies, deal sizes, and healthcare subsectors.

Deal activity was equally impressive. Investors announced approximately 445 buyout transactions during the year, marking the second-highest annual total on record behind only 2021. The convergence of robust deal volume and record-setting value underscores the depth of investor conviction in healthcare as a resilient, high-growth asset class. According to Bain & Company’s 2026 Global Healthcare Private Equity Report, this performance reflects two structural tailwinds: high levels of dry powder seeking deployment and a growing cohort of sponsor-owned assets reaching the end of their fund lives.

The year also witnessed a dramatic rebound in exit activity. Exit value reached its second-highest year ever at an expected $156 billion, while exit volume ranked third all-time. The leap from $54 billion in 2024 was propelled by a sharp increase in large transactions, with over 40 exits exceeding $1 billion compared to just 16 in the prior year. For investors seeking to understand how interactive analysis tools can transform complex healthcare PE data into actionable insights, this market cycle provides a compelling case study.

Regional Performance: Europe Leads the Charge

European healthcare PE dealmaking rose sharply in 2025, with deal value more than doubling to an estimated $59 billion. This represented one of the most dramatic regional surges in healthcare PE history, driven primarily by robust biopharma activity and the reemergence of large-cap transactions. The top five deals alone accounted for approximately 65% of total European deal value, reflecting the concentration of capital in high-conviction opportunities.

The large-cap resurgence was particularly striking. Some 15 deals exceeded $1 billion in 2025, compared with just 3 and 4 deals above that threshold in 2023 and 2024, respectively. Deal count also grew meaningfully, outpacing 2024’s previous high-water mark and continuing an upward trend that began in 2022. Europe’s relative insulation from the tariff shocks and trade tensions that affected North America and Asia-Pacific during the second quarter contributed to sustained activity throughout the year.

Exit activity in Europe rose substantially to an estimated $53 billion after a steep decline in 2024. Large sponsor-to-sponsor transactions led the recovery, including landmark deals such as the announced sale by Bain Capital and Cinven of a majority stake in STADA Arzneimittel AG to a group led by CapVest Partners. This transaction exemplified how European healthcare assets have become increasingly attractive to global PE investors seeking stable, cash-generative platforms with regulatory moats. Research from the World Health Organization continues to highlight growing healthcare demand across European markets, providing a favorable long-term backdrop for PE investment.

North America Rebounds After Tariff Turbulence

Macroeconomic and policy uncertainties in the second quarter drove a significant pullback in North American healthcare PE activity, with deal count and value declining 19% and 37% respectively from the first quarter. The announcement of sweeping tariff policies in April created immediate uncertainty around supply chains, pharmaceutical pricing, and cross-border deal structures.

Despite this temporary retreat, North America delivered a healthy full-year performance, bolstered by an uptick in deals exceeding $1 billion. Twenty-six transactions surpassed this threshold through November 2025, compared with 14 in the full year 2024. Notably, more than 70% of these large deals were sponsor-to-sponsor transactions, reflecting the maturity of the North American healthcare PE ecosystem and the growing prevalence of continuation strategies.

Exit activity proved even more robust, rising to an expected $90 billion from $35 billion in 2024. This more than doubling of exit value was driven by both sponsor-to-sponsor sales and a resurgence in corporate acquisitions of PE-owned healthcare assets. The recovery in North America demonstrates the market’s resilience and the ability of experienced healthcare PE investors to navigate policy uncertainty while maintaining disciplined deployment strategies. For professionals tracking these market dynamics, Libertify’s interactive reports provide real-time, data-driven analysis of cross-border deal trends.

Asia-Pacific Sets New Deal Value Records

In Asia-Pacific, healthcare PE deal value set an all-time record for the year, exceeding 2021’s previous high by more than 30% despite a second-quarter slowdown linked to global trade tensions. Investment spanned greater breadth and depth across countries and sectors than in previous cycles, with biopharma and provider services continuing to drive the majority of activity while medtech and healthcare IT showed meaningful growth.

Provider and hospital deals emerged as a persistent and expanding theme, with deal value expected to double from $5 billion in 2024 to more than $10 billion for full-year 2025. This growth reflects accelerating site-of-care migration trends and the increasing sophistication of healthcare delivery models across the region. Japan, India, and Australia-New Zealand all saw notable growth since 2024.

Greater China’s rebound was perhaps the most dramatic, with activity more than doubling its 2024 performance in both volume and value. This recovery was driven primarily by biopharma and medtech transactions, although overall activity remained below the historical highs reached in previous years. China’s world-class pharmaceutical pipeline and growing medtech innovation ecosystem continue to attract significant PE interest, supported by data from the McKinsey Global Institute’s healthcare research highlighting Asia’s expanding healthcare spending.

Biopharma Dominates Healthcare PE Deal Flow

Biopharma remained the cornerstone of healthcare PE investment in 2025, with deal value rising to an estimated $80 billion from $55 billion in 2024. Volume increased nearly 20% to more than 130 deals, reinforcing the sector’s position as the most active segment in healthcare PE. Biopharma has consistently accounted for approximately 30% of overall deal volume and at least 22% of deal value each year since 2020.

Europe drove much of this momentum, with a nearly 40% increase in deal volume and 70% increase in deal value compared to 2024. This regional strength reflected growing PE appetite for European pharmaceutical assets that are less exposed to the pricing and reimbursement pressures prevalent in the US market. Investors increasingly targeted contract development and manufacturing organizations (CDMOs), generics, consumer health, and animal health segments.

Exit activity within biopharma was similarly robust, especially within pharma IT subsegments. Notable corporate exits included Nordic Capital and Astorg’s sale of Clario, a tech-driven contract research organization, to Thermo Fisher Scientific for nearly $9 billion, and Insight Partners’ sale of Dotmatics, a cloud software provider for pharmaceutical R&D, to Siemens for more than $5 billion. These transactions underscore the premium valuations achievable for technology-enabled biopharma services platforms. Analysis from the U.S. Food and Drug Administration shows accelerating drug approvals that further support biopharma deal rationale.

Provider Services and Healthcare IT Surge

Provider and related services deal value jumped 57% over 2024 to an estimated $62 billion in 2025. While volume remained flat from the prior year, the shift toward higher-value deals reflected investors’ sharpened focus on technology-enabled assets such as analytics, workforce optimization, and platform solutions. Healthcare IT deal value within the provider segment doubled to an estimated $32 billion, led by transactions like Warburg Pincus’s sale of its majority interest in ModMed to Clearlake Capital at a valuation exceeding $5 billion.

Broader provider dealmaking trends encompassed several high-conviction themes that have defined the sector’s evolution in recent years. Site-of-care migration continued to drive investment as healthcare delivery shifts from acute care settings to outpatient and ambulatory environments. Retail healthcare M&A, particularly in dental and veterinary services, remained active as platforms pursued roll-up strategies to build scale. Lab and diagnostic platforms attracted capital as demand for precision medicine and population health analytics grew.

Workforce and staffing solutions represented another significant area of investment as healthcare systems globally grappled with persistent labor shortages. PE investors recognized the critical role of technology in addressing workforce challenges, from AI-powered scheduling platforms to virtual care delivery models. These themes collectively demonstrate how healthcare IT has become inseparable from provider services, creating hybrid investment opportunities that combine recurring revenue models with essential healthcare infrastructure.

Medtech Emerges as a Private Equity Growth Engine

Medtech gained significant momentum in 2025, with deal value nearly doubling over the prior year to an estimated $33 billion and volume increasing nearly 20% to approximately 88 deals. This acceleration established medtech as one of the fastest-growing segments within healthcare PE, driven by investors applying proven value-creation playbooks focused on revenue growth, margin expansion, and multiple expansion while managing downside risk.

The segment was particularly attractive for large-scale assets originating from public markets, whether through take-privates or carve-outs. Carlyle Group’s acquisition of Vantive, a global renal care business carved out from Baxter, exemplified this trend. The most transformative deal was Blackstone and TPG’s $18.3 billion acquisition of Hologic in a take-private transaction that accounted for more than half of projected medtech buyout activity for the year.

Perhaps the most significant medtech event of 2025 came at year’s end: Medline’s initial public offering raised more than $6 billion at a valuation exceeding $50 billion, marking the largest PE-backed IPO in history. Originally acquired in 2021 for approximately $34 billion by a consortium led by Blackstone, Carlyle Group, and Hellman & Friedman, the Medline IPO demonstrated the extraordinary returns achievable in medtech through operational improvement and strategic growth. For analysts examining the intersection of medtech and PE returns, interactive data visualization provides deeper insight into sector performance patterns.

Sponsor-to-Sponsor Deals Hit Record Highs

After a slowdown in 2023 and 2024, sponsor-to-sponsor deals surged to record highs in 2025. Both volume and value set new benchmarks, with more than 150 sponsor-to-sponsor transactions expected and estimated value exceeding $120 billion. This dramatic recovery signaled the healthcare PE market’s underlying strength and the growing sophistication of secondary market transactions.

The scale of individual sponsor-to-sponsor deals also expanded significantly, with more than 30 transactions exceeding $1 billion in 2025—a sharp rise from just eight such deals in 2024. These large-cap secondary transactions increasingly involve consortium structures and continuation vehicles, allowing PE firms to manage portfolio maturity while maintaining exposure to high-performing healthcare assets.

In addition to sponsor-to-sponsor activity, public-to-private deals and carve-outs continued to present alternative pathways for healthcare PE investors. Both deal types grew on an absolute basis since 2023, reflecting the diversification of PE entry strategies beyond traditional private company acquisitions. The combination of robust sponsor-to-sponsor activity, growing take-private transactions, and active carve-out markets provides healthcare PE firms with multiple avenues for capital deployment across the risk-return spectrum.

Large-Cap Healthcare Deals Drive Outsized Growth

Healthcare PE deal value saw a significant boost compared with volume in 2025, largely driven by growth in transactions exceeding $1 billion. The expansion of large-cap activity reflected heightened investor interest in high-valued segments such as medtech and healthcare IT, where scale platforms command premium valuations due to their market positions, recurring revenue characteristics, and operational leverage potential.

For deals below the $1 billion threshold, volume rose 56% during the year, although activity remained below the previous high-water mark set in 2021. This mid-market recovery indicates broadening participation across the healthcare PE landscape, with a growing number of funds deploying capital into specialty services, single-specialty provider platforms, and niche pharmaceutical segments.

The divergence between deal value and deal count growth underscores a key structural trend in healthcare PE: capital concentration in larger, more complex transactions that offer greater operational improvement potential and clearer pathways to value creation. This dynamic is likely to persist as the largest healthcare PE firms continue to raise increasingly large funds and seek deployment opportunities commensurate with their fund sizes.

Healthcare PE Outlook: What Lies Ahead in 2026

The strong performance of healthcare PE in 2025 establishes favorable conditions heading into 2026. Several structural tailwinds support continued robust activity: historically high levels of dry powder across healthcare-focused and generalist PE funds, a growing cohort of portfolio assets approaching optimal exit windows, easing interest rates that improve deal financing economics, and robust IPO market conditions following the landmark Medline offering.

Sector-specific dynamics also support an optimistic outlook. The aging global population continues to drive healthcare demand across all subsectors. Technology-enabled healthcare services are creating new categories of investable assets that combine the defensive characteristics of healthcare with the growth profiles of technology companies. Precision medicine, digital health, and AI-powered diagnostics represent emerging frontiers for PE investment.

However, investors must navigate ongoing challenges including elevated asset valuations, regulatory uncertainty in key markets, and the complexity of creating value in an increasingly competitive deal environment. The most successful healthcare PE firms in 2026 will be those that combine deep sector expertise with operational improvement capabilities and creative deal structuring to generate returns in a higher-cost-of-capital environment. As healthcare private equity continues to mature as an asset class, the bar for differentiated performance continues to rise.